• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

难溶性化合物共结晶的溶出度改善及其改善机制

Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds.

作者信息

Shiraki Koji, Takata Noriyuki, Takano Ryusuke, Hayashi Yoshiki, Terada Katsuhide

机构信息

Discovery Platform Technology Department, Chugai Pharmaceutical Co. Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan.

出版信息

Pharm Res. 2008 Nov;25(11):2581-92. doi: 10.1007/s11095-008-9676-2. Epub 2008 Jul 24.

DOI:10.1007/s11095-008-9676-2
PMID:18651208
Abstract

PURPOSE

To demonstrate improvement in the dissolution of exemestane and megestrol acetate from cocrystallization using various particle sizes and to investigate the mechanism of the improved dissolution.

METHODS

Cocrystal screening was performed by slurry crystallization. The cocrystals were identified and characterized by powder X-ray diffraction, thermal analysis, and single crystal X-ray diffraction. Different particle sizes of each cocrystal were prepared from organic solutions. Solubility and dissolution rates were evaluated using dissolution tests. Transformation behavior of the cocrystals in suspension was analyzed by PXRD and polarization microscopy.

RESULTS

Two novel cocrystals were obtained: exemestane (EX)/maleic acid (MAL) (cocrystal 1) and megestrol acetate (MA)/saccharin (SA) (cocrystal 2). Cocrystal 1 showed a high dissolution rate even with large particles. Cocrystal 2 showed supersaturation with fine particles. The transformation from cocrystal 1 to EX was observed within 1 min in suspension. Cocrystal 2 was transformed to MA within 2-4 h.

CONCLUSIONS

Cocrystallizations of EX and MA improved initial dissolution rates compared to the respective original crystals. The mechanism of dissolution enhancement varied. With cocrystal 1, fine particle formation resulted in enhancement, whereas with cocrystal 2, enhancement was due to the maintenance of the cocrystal form and rapid dissolution before transformation to the original crystal.

摘要

目的

通过使用不同粒径的共结晶来证明依西美坦和醋酸甲地孕酮的溶出度提高,并研究溶出度提高的机制。

方法

通过淤浆结晶进行共晶筛选。通过粉末X射线衍射、热分析和单晶X射线衍射对共晶进行鉴定和表征。从有机溶液中制备每种共晶的不同粒径。使用溶出度试验评估溶解度和溶出速率。通过粉末X射线衍射和偏光显微镜分析共晶在悬浮液中的转变行为。

结果

获得了两种新型共晶:依西美坦(EX)/马来酸(MAL)(共晶1)和醋酸甲地孕酮(MA)/糖精(SA)(共晶2)。即使是大颗粒,共晶1也显示出高溶出速率。共晶2对细颗粒显示出过饱和现象。在悬浮液中观察到共晶1在1分钟内转变为依西美坦。共晶2在2 - 4小时内转变为醋酸甲地孕酮。

结论

与各自的原始晶体相比,依西美坦和醋酸甲地孕酮的共结晶提高了初始溶出速率。溶出增强的机制各不相同。对于共晶1,细颗粒的形成导致溶出增强,而对于共晶2,增强是由于共晶形式的维持以及在转变为原始晶体之前的快速溶解。

相似文献

1
Dissolution improvement and the mechanism of the improvement from cocrystallization of poorly water-soluble compounds.难溶性化合物共结晶的溶出度改善及其改善机制
Pharm Res. 2008 Nov;25(11):2581-92. doi: 10.1007/s11095-008-9676-2. Epub 2008 Jul 24.
2
Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization.吲哚美辛-糖精共晶体:设计、合成及初步药物表征
Pharm Res. 2008 Mar;25(3):530-41. doi: 10.1007/s11095-007-9394-1. Epub 2007 Aug 17.
3
Novel cocrystals of itraconazole: Insights from phase diagrams, formation thermodynamics and solubility.伊曲康唑新型共晶:相图、形成热力学和溶解度的见解。
Int J Pharm. 2021 Apr 15;599:120441. doi: 10.1016/j.ijpharm.2021.120441. Epub 2021 Mar 3.
4
Pharmaceutical characterisation and evaluation of cocrystals: Importance of in vitro dissolution conditions and type of coformer.药物共晶的药物特性描述和评估:体外溶解条件和共晶形成剂类型的重要性。
Int J Pharm. 2013 Sep 10;453(2):380-8. doi: 10.1016/j.ijpharm.2013.05.048. Epub 2013 May 29.
5
Ultrasound assisted cocrystallization from solution (USSC) containing a non-congruently soluble cocrystal component pair: Caffeine/maleic acid.超声辅助溶液共结晶法(USSC)中包含非一致可溶共晶组分对:咖啡因/马来酸。
Eur J Pharm Sci. 2010 Dec 23;41(5):597-602. doi: 10.1016/j.ejps.2010.08.012. Epub 2010 Aug 27.
6
Mechanisms by which moisture generates cocrystals.水分产生共晶体的机制。
Mol Pharm. 2007 May-Jun;4(3):360-72. doi: 10.1021/mp0700099. Epub 2007 May 8.
7
Thermodynamic and kinetic investigation on the crucial factors affecting adefovir dipivoxil-saccharin cocrystallization.关于影响阿德福韦酯-糖精共结晶的关键因素的热力学和动力学研究。
Pharm Res. 2014 Jul;31(7):1766-78. doi: 10.1007/s11095-013-1281-3. Epub 2014 Feb 13.
8
The role of pH and dose/solubility ratio on cocrystal dissolution, drug supersaturation and precipitation.pH值和剂量/溶解度比在共晶溶解、药物过饱和及沉淀方面的作用。
Eur J Pharm Sci. 2020 Sep 1;152:105422. doi: 10.1016/j.ejps.2020.105422. Epub 2020 Jun 10.
9
Effects of Coformer and Polymer on Particle Surface Solution-Mediated Phase Transformation of Cocrystals in Aqueous Media.共晶形成剂和聚合物对水介质中共晶粒子表面溶液介导的相转变的影响。
Mol Pharm. 2020 Oct 5;17(10):3825-3836. doi: 10.1021/acs.molpharmaceut.0c00587. Epub 2020 Sep 11.
10
Feasibility of electrospray deposition for rapid screening of the cocrystal formation and single step, continuous production of pharmaceutical nanococrystals.电喷雾沉积法快速筛选共晶形成和一步连续生产药物纳米共晶的可行性。
Drug Dev Ind Pharm. 2018 Jun;44(6):1034-1047. doi: 10.1080/03639045.2018.1430821. Epub 2018 Feb 1.

引用本文的文献

1
Crystal Engineering of Ionic Cocrystals Sustained by Azolium···Azole Heterosynthons.由唑鎓···唑杂合成子支撑的离子共晶体的晶体工程
Pharmaceutics. 2022 Oct 28;14(11):2321. doi: 10.3390/pharmaceutics14112321.
2
The Relevance of Crystal Forms in the Pharmaceutical Field: Sword of Damocles or Innovation Tools?晶体形式在制药领域的相关性:达摩克利斯之剑还是创新工具?
Int J Mol Sci. 2022 Aug 12;23(16):9013. doi: 10.3390/ijms23169013.
3
Improving the solubility and bioavailability of anti-hepatitis B drug PEC PEC-fumaric acid cocrystal.

本文引用的文献

1
Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.依西美坦联合雷洛昔芬在有乳腺癌病史的绝经后妇女中的药代动力学及耐受性
Breast Cancer Res Treat. 2008 Sep;111(2):377-88. doi: 10.1007/s10549-007-9787-1. Epub 2007 Oct 20.
2
Megestrol acetate in cachexia and anorexia.醋酸甲地孕酮用于恶病质和厌食症。
Int J Nanomedicine. 2006;1(4):411-6. doi: 10.2147/nano.2006.1.4.411.
3
Indomethacin-saccharin cocrystal: design, synthesis and preliminary pharmaceutical characterization.
提高抗乙肝药物PEC——PEC-富马酸共晶体的溶解度和生物利用度。
RSC Adv. 2020 Oct 2;10(59):36125-36134. doi: 10.1039/d0ra06608g. eCollection 2020 Sep 28.
4
Effect of Coformer Selection on In Vitro and In Vivo Performance of Adefovir Dipivoxil Cocrystals.共晶形成剂选择对阿德福韦酯共晶的体外和体内性能的影响。
Pharm Res. 2021 Oct;38(10):1777-1791. doi: 10.1007/s11095-021-03116-7. Epub 2021 Nov 2.
5
Simvastatin-Nicotinamide Co-Crystals: Formation, Pharmaceutical Characterization and in vivo Profile.辛伐他汀-烟酰胺共晶:形成、药物特性及体内概况。
Drug Des Devel Ther. 2020 Oct 19;14:4303-4313. doi: 10.2147/DDDT.S270742. eCollection 2020.
6
Improving the Solubility and Bioavailability of Pemafibrate via a New Polymorph Form II.通过新型II型多晶型物提高匹伐他汀的溶解度和生物利用度。
ACS Omega. 2020 Oct 1;5(40):26245-26252. doi: 10.1021/acsomega.0c04005. eCollection 2020 Oct 13.
7
Superior Solubility and Dissolution of Zaltoprofen via Pharmaceutical Cocrystals.通过药物共晶体提高扎托洛芬的溶解度和溶出度。
Turk J Pharm Sci. 2019 Sep;16(3):310-316. doi: 10.4274/tjps.galenos.2018.15013. Epub 2019 Jul 10.
8
Pharmaceutical Co-Crystallization: Regulatory Aspects, Design, Characterization, and Applications.药物共结晶:监管方面、设计、表征及应用
Adv Pharm Bull. 2020 Jun;10(2):203-212. doi: 10.34172/apb.2020.024. Epub 2020 Feb 18.
9
Crystal engineering of exemestane to obtain a co-crystal with enhanced urease inhibition activity.依西美坦的晶体工程以获得具有增强脲酶抑制活性的共晶体。
IUCrJ. 2020 Jan 1;7(Pt 1):105-112. doi: 10.1107/S2052252519016142.
10
Dissolution Advantage of Nitazoxanide Cocrystals in the Presence of Cellulosic Polymers.硝唑尼特共晶体在纤维素聚合物存在下的溶出优势。
Pharmaceutics. 2019 Dec 25;12(1):23. doi: 10.3390/pharmaceutics12010023.
吲哚美辛-糖精共晶体:设计、合成及初步药物表征
Pharm Res. 2008 Mar;25(3):530-41. doi: 10.1007/s11095-007-9394-1. Epub 2007 Aug 17.
4
Megestrol acetate NCD oral suspension -- Par Pharmaceutical: megestrol acetate nanocrystal dispersion oral suspension, PAR 100.2, PAR-100.2.醋酸甲地孕酮非专利口服混悬液——帕尔制药公司:醋酸甲地孕酮纳米晶体分散口服混悬液,PAR 100.2,PAR - 100.2。
Drugs R D. 2007;8(4):251-4. doi: 10.2165/00126839-200708040-00005.
5
Celecoxib:nicotinamide dissociation: using excipients to capture the cocrystal's potential.塞来昔布:烟酰胺解离:利用辅料挖掘共晶的潜力。
Mol Pharm. 2007 May-Jun;4(3):386-400. doi: 10.1021/mp0700108. Epub 2007 May 12.
6
The salt-cocrystal continuum: the influence of crystal structure on ionization state.盐 - 共晶体连续体:晶体结构对电离态的影响。
Mol Pharm. 2007 May-Jun;4(3):323-38. doi: 10.1021/mp0601345. Epub 2007 Apr 27.
7
Efficient co-crystal screening using solution-mediated phase transformation.利用溶液介导的相变进行高效共晶筛选。
J Pharm Sci. 2007 May;96(5):990-5. doi: 10.1002/jps.20949.
8
Crystallization pathways and kinetics of carbamazepine-nicotinamide cocrystals from the amorphous state by in situ thermomicroscopy, spectroscopy, and calorimetry studies.通过原位热显微镜、光谱学和量热法研究,非晶态卡马西平-烟酰胺共晶体的结晶途径和动力学。
J Pharm Sci. 2007 May;96(5):1147-58. doi: 10.1002/jps.20945.
9
Designing a molecular delivery system within a preclinical timeframe.在临床前阶段设计一种分子递送系统。
Drug Discov Today. 2007 Mar;12(5-6):189-99. doi: 10.1016/j.drudis.2007.01.006. Epub 2007 Feb 9.
10
Quantifying solubility enhancement due to particle size reduction and crystal habit modification: case study of acetyl salicylic acid.量化因粒径减小和晶习改变导致的溶解度增强:乙酰水杨酸的案例研究
J Pharm Sci. 2007 Aug;96(8):1967-73. doi: 10.1002/jps.20869.